First National Advisers LLC Trims Stake in Revvity, Inc. (NYSE:RVTY)

First National Advisers LLC cut its stake in Revvity, Inc. (NYSE:RVTY - Free Report) by 35.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,238 shares of the company's stock after selling 5,685 shares during the quarter. First National Advisers LLC's holdings in Revvity were worth $1,143,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Gladius Capital Management LP bought a new position in Revvity in the third quarter valued at about $32,000. Assetmark Inc. lifted its stake in shares of Revvity by 3,700.0% in the 4th quarter. Assetmark Inc. now owns 266 shares of the company's stock worth $30,000 after purchasing an additional 259 shares during the period. Continuum Advisory LLC boosted its holdings in shares of Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company's stock worth $43,000 after buying an additional 327 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Revvity by 55.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company's stock valued at $43,000 after buying an additional 138 shares during the period. Finally, Avior Wealth Management LLC increased its holdings in Revvity by 7,980.0% during the third quarter. Avior Wealth Management LLC now owns 404 shares of the company's stock valued at $52,000 after buying an additional 399 shares during the last quarter. 86.65% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Revvity

In related news, insider Joel S. Goldberg sold 15,170 shares of Revvity stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total value of $1,922,494.10. Following the completion of the transaction, the insider now owns 33,400 shares in the company, valued at approximately $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Tajinder S. Vohra sold 5,492 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,295,550.12. This trade represents a 21.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.60% of the company's stock.

Remove Ads

Analysts Set New Price Targets

RVTY has been the subject of a number of recent research reports. Sanford C. Bernstein downgraded shares of Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price objective for the company. in a research report on Friday, January 10th. Barclays boosted their price target on Revvity from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Raymond James reaffirmed an "outperform" rating and issued a $145.00 price objective (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. KeyCorp boosted their price objective on Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Bank of America upgraded shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 target price on the stock in a research note on Friday, December 13th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $136.25.

Revvity Price Performance

Shares of NYSE:RVTY traded down $2.96 during midday trading on Thursday, reaching $106.96. 1,078,999 shares of the company were exchanged, compared to its average volume of 964,183. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41. The stock has a market cap of $12.85 billion, a PE ratio of 48.40, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06. The business's fifty day moving average is $116.76 and its two-hundred day moving average is $117.74. Revvity, Inc. has a one year low of $97.32 and a one year high of $129.50.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 earnings per share for the quarter, beating analysts' consensus estimates of $1.37 by $0.05. Revvity had a return on equity of 7.68% and a net margin of 9.81%. During the same quarter last year, the business earned $1.25 earnings per share. As a group, analysts predict that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date is Thursday, April 17th. Revvity's payout ratio is 12.67%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.